camptothecin has been researched along with bilirubin in 39 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (7.69) | 18.2507 |
2000's | 26 (66.67) | 29.6817 |
2010's | 10 (25.64) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cvitkovic, E; Goldwasser, F; Lokiec, F; Mahjoubi, M; Misset, JL; Myara, A; Trivin, F; Wasserman, E | 1 |
Coffman, BL; Green, MD; Iyer, L; King, CD; Ratain, MJ; Roy, SK; Tephly, TR; Whitington, PF | 1 |
Das, S; Di Rienzo, A; Hall, D; Iyer, L; Kim, S; Mortell, MA; Ramírez, J; Ratain, MJ | 1 |
Ando, Y; Hasegawa, Y; Ichiki, M; Shimokata, K; Sugiyama, T; Ueoka, H | 1 |
Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Jacques, C; Raymond, E; Rixe, O; Sanderink, GJ; Vernillet, L | 1 |
Cheng, C; Das, S; Di Rienzo, A; Grimsley, C; Innocenti, F; Kuttab-Boulos, H; Ramírez, J; Ratain, MJ | 1 |
Atherton, PJ; Gupta, E; Kastrissios, H; Klein, CE; Pitot, HC; Ratain, MJ; Reid, JM; Sloan, JA | 1 |
Fuchs, CS; Harker, G; Hecht, JR; Moore, MR; Rinaldi, D; Villa, L | 1 |
Chen, PX; Das, S; Innocenti, F; Iyer, L; Janisch, L; Karrison, T; Kocherginsky, M; Ramírez, J; Ratain, MJ; Rudin, CM; Undevia, SD; Vokes, EE | 1 |
Fuchs, CS; Kwok, A; McGovren, JP; Meyerhardt, JA; Ratain, MJ | 1 |
Hasegawa, R; Jinno, H; Kamakura, S; Kamatani, N; Kaniwa, N; Katori, N; Kitakaze, M; Kitamura, Y; Komamura, K; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Ueno, K; Yoshida, T | 1 |
Gourgou-Bourgade, S; Kramar, A; Ychou, M | 1 |
Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
Boige, V; Debaere, T; Ducreux, M; Hannoun, L; Hebbar, M; Magherini, E; Malka, D; Mignard, D; Poynard, T; Taïeb, J | 1 |
Crews, KR | 1 |
Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
Du, J; Feng, G; He, L; Li, X; Qin, S; Wang, L; Xing, Q; Xu, L; Xu, M; Yu, L; Zhang, A | 1 |
Hahn, KK; Kolesar, JM; Wolff, JJ | 1 |
Booth, BP; Gobburu, JV; Ibrahim, A; Innocenti, F; Johnson, JR; Mehta, M; Rahman, A; Ramchandani, RP; Ratain, MJ; Wang, Y | 1 |
Fujiwara, Y; Fukui, T; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Simmyo, Y; Tamura, T; Yamada, K; Yamamoto, N | 1 |
Kado, S; Kaneda, N; Kato, I; Kurita, A; Matsumoto, T; Onoue, M; Uchida, K; Yokokura, T | 1 |
Hirohashi, S; Kaniwa, N; Kurose, K; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shirao, K; Yoshida, T | 1 |
Barrett, J; Bernstein, ML; Blaney, SM; Bomgaars, L; Gupta, M; Mondick, J; Rosner, GL; Thompson, PA; Yu, A | 1 |
Chen, PM; Chen, WS; Chiou, TJ; Jiang, JK; Lin, JK; Lin, TC; Liu, CY; Liu, JH; Wang, HS; Wang, WS | 1 |
Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP | 1 |
Chen, P; Das, S; Dolan, ME; Innocenti, F; Kroetz, DL; Ramírez, J; Ratain, MJ; Relling, M; Rosner, GL; Schuetz, E | 1 |
Harada, M; Isobe, H; Izumi, K; Mino, K; Saito, K; Tanaka, H | 1 |
Boeck, S; Heinemann, V; Schulz, C; Stemmler, HJ | 1 |
Attinà, G; Coccia, P; Riccardi, R; Ruggiero, A; Scalzone, M | 1 |
Strassburg, CP | 1 |
Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C | 1 |
Auperin, A; Bize, P; de Baere, T; Denys, A; Deschamps, F; Drouard-Troalen, L; Paci, A; Pascale, F; Rao, PP; Seck, A; Teriitheau, C | 1 |
Fukami, K; Hasegawa, J; Hirose, K; Kaneda, N; Kitamura, M; Maeda, Y; Maruo, E; Takada, H; Yamashita, K | 1 |
Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J | 1 |
Combalia, A; Dubreuil, M; Guañabens, N; Monegal, A; Parés, A; Peris, P; Ruiz-Gaspà, S | 1 |
Azuma, S; Kawato, N; Makihara, K; Nakata, I; Ueno, H | 1 |
Ando, Y; Fujita, K; Ichikawa, W; Minamimura, K; Miyauchi, H; Morita, S; Moriwaki, T; Nakamura, M; Ohashi, Y; Okutani, Y; Sadahiro, S; Sakata, Y; Shinozaki, K; Sugihara, M; Sugiyama, T; Takahashi, T; Takii, Y; Tanaka, C; Tsuji, A; Uehara, K | 1 |
Hu, GY; Huang, L; Li, QX; Li, ZH; Liao, X; Liu, B; Qiu, H; Yu, QQ; Yuan, XL; Zhang, MS | 1 |
Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS | 1 |
4 review(s) available for camptothecin and bilirubin
Article | Year |
---|---|
Pharmacogenetics and irinotecan therapy.
Topics: Antineoplastic Agents; Bilirubin; Biomarkers; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Labeling; Genetic Predisposition to Disease; Genetic Testing; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic; Risk Assessment | 2006 |
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic | 2008 |
UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Pharmacological; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Genotype; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Models, Biological; Neoplasm Metastasis; Polymorphism, Genetic; Precision Medicine; Racial Groups | 2009 |
Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diagnosis, Differential; Genetic Predisposition to Disease; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia, Hereditary; Irinotecan; Jaundice, Chronic Idiopathic; Neoplasms | 2010 |
7 trial(s) available for camptothecin and bilirubin
Article | Year |
---|---|
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Humans; Hyperbilirubinemia; Irinotecan; Male; Middle Aged; Predictive Value of Tests | 2002 |
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
Topics: Adult; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Creatinine; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucuronates; Humans; Infusions, Intravenous; Irinotecan; Kidney Function Tests; Liver Function Tests; Male; Oxidoreductases; Predictive Value of Tests; Reproducibility of Results | 2002 |
Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Prospective Studies; Quality of Life; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2003 |
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Cirrhosis; Liver Neoplasms; Male | 2006 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Biomarkers, Tumor; Camptothecin; Chi-Square Distribution; China; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pharmacogenomic Variants; Phenotype; Predictive Value of Tests; Prospective Studies; ROC Curve; Treatment Outcome; Young Adult | 2016 |
28 other study(ies) available for camptothecin and bilirubin
Article | Year |
---|---|
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
Topics: Bilirubin; Camptothecin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gilbert Disease; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1997 |
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Causality; Crigler-Najjar Syndrome; Glucuronosyltransferase; Guanine; Humans; Irinotecan; Isoenzymes; Microsomes, Liver; Nitrophenols; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Uridine Diphosphate; Zidovudine | 1998 |
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver; Phenotype; Polymorphism, Genetic; Promoter Regions, Genetic | 1999 |
Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Enzyme Inhibitors; Female; Glucuronates; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Polymorphism, Genetic | 2002 |
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
Topics: Base Sequence; Bilirubin; Black or African American; Camptothecin; Genotype; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Linkage Disequilibrium; Microsomes, Liver; Molecular Sequence Data; Phenobarbital; Polymorphism, Genetic; Promoter Regions, Genetic; Topoisomerase I Inhibitors; White People | 2002 |
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Female; Genetic Variation; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neutropenia; Prospective Studies; Risk; Topoisomerase I Inhibitors | 2004 |
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Topoisomerase I Inhibitors | 2004 |
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
Topics: Aged; Bilirubin; Camptothecin; Female; Genetic Linkage; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide | 2004 |
Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Monitoring, Physiologic; Neutropenia; Reproducibility of Results | 2005 |
Individualizing chemotherapeutic treatment of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Camptothecin; Cetuximab; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Pharmacogenetics; United States | 2006 |
Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations.
Topics: Adult; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Bone Marrow Diseases; Camptothecin; China; Ethnicity; Exons; Female; Gastrointestinal Diseases; Gene Frequency; Genetic Predisposition to Disease; Glucuronosyltransferase; Haplotypes; Heterozygote; Homozygote; Humans; Hyperbilirubinemia; Irinotecan; Linkage Disequilibrium; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Reference Values; TATA Box | 2007 |
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Female; Glucuronosyltransferase; Humans; Irinotecan; Lymphoma; Male; Models, Biological; Neutropenia; Polymorphism, Genetic; Regression Analysis | 2007 |
Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cisplatin; Diarrhea; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies | 2007 |
Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diarrhea; Glucuronosyltransferase; Hyperbilirubinemia; Intestines; Irinotecan; Rats; Rats, Gunn; Rats, Wistar | 2008 |
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Retrospective Studies | 2008 |
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Bilirubin; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Female; Glucuronates; Glucuronosyltransferase; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Models, Biological; Multicenter Studies as Topic; Neoplasms | 2008 |
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic; Retrospective Studies | 2008 |
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biotransformation; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Glucuronides; Glucuronosyltransferase; Hepatocyte Nuclear Factor 1-alpha; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Multivariate Analysis; Neutropenia; Organic Anion Transporters; Patient Selection; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
[Assessment of total bilirubin or SN-38/SN-38G ratio as a predictor of severe irinotecan toxicity].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Female; Glucuronates; Humans; Individuality; Irinotecan; Lung Neoplasms; Male; Middle Aged; Small Cell Lung Carcinoma | 2009 |
Treatment of childhood sarcoma with irinotecan: bilirubin level as a predictor of gastrointestinal toxicity.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Child; Child, Preschool; Diarrhea; Female; Gastric Mucosa; Humans; Infant; Intestinal Mucosa; Irinotecan; Male; Predictive Value of Tests; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2009 |
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin | 2011 |
Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Bilirubin; Camptothecin; Chemoembolization, Therapeutic; Drug Delivery Systems; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Rabbits; Statistics, Nonparametric | 2012 |
Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Glucuronates; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic | 2014 |
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult | 2014 |
Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Bilirubin; Camptothecin; Cell Line, Tumor; Cholagogues and Choleretics; Detergents; Humans; Lithocholic Acid; Osteoblasts; Up-Regulation; Ursodeoxycholic Acid | 2014 |
Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Retrospective Studies | 2015 |
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Topics: Aged; Alleles; Asian People; Bilirubin; Camptothecin; Colorectal Neoplasms; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Neutrophils; Nomograms; Prospective Studies | 2015 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Bone Neoplasms; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2017 |